BioSpace News Archive

Braxia Scientific Corp., a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce it has launched its psilocybin-assisted clinical therapy training program.

Exicure, Inc.®, a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that CEO David Giljohann will present a company update as well as participate in a series of 1x1 meetings at the Ladenburg Thalmann 2021 Healthcare Conference occurring July 13-14, 2021.

Charles River Laboratories International, Inc. announced that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments.

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced the U.S. launch and first patient implant of the FORZA™ Ti PLIF Spacer System.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal diseases, announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease.

CicloMed LLC. today announced that the Phase 1B clinical trial of fosciclopirox for the treatment of bladder cancer is now open.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced with great sadness the passing of longtime Board Member, William J. Kennedy, PhD.

Bristol Myers Squibb announced that the European Commission has approved Opdivo plus Yervoy for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.

Eikon Therapeutics, Inc. today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer.

Takeda Pharmaceutical Company Limited today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”).